Author: Khirstyn-Lien

Journal of Epidemiology
Date: May 8, 2026

Abstract

Hantaviruses are enveloped, single-stranded negative-sense RNA viruses belonging to the family Hantaviridae within the order Bunyavirales. These zoonotic pathogens are maintained primarily in rodent reservoirs and may cause severe human disease following aerosolized exposure to infected rodent excreta. Two principal syndromes are associated with hantavirus infection: hantavirus cardiopulmonary syndrome (HCPS), also termed hantavirus pulmonary syndrome (HPS), and hemorrhagic fever with renal syndrome (HFRS). Recent international concern has emerged following a 2026 outbreak involving Andes hantavirus aboard an expedition cruise vessel, renewing attention toward the limited but documented potential for human to human transmission. Current evidence indicates that hantavirus infections remain relatively uncommon globally; however, severe HCPS may exhibit mortality rates approaching 40–50%. This review summarizes current scientific knowledge regarding hantavirus molecular biology, viral structure, epidemiology, transmission, pathogenesis, diagnosis, treatment, prevention, and contemporary outbreak developments.  

Introduction

Hantaviruses are emerging zoonotic RNA viruses distributed worldwide through persistent infection in rodent hosts. Human infection typically occurs following inhalation of aerosolized viral particles originating from rodent urine, feces, or saliva. Unlike highly transmissible respiratory RNA viruses, most hantaviruses do not spread efficiently between humans. The Andes virus strain identified in South America represents the only hantavirus with confirmed limited human-to-human transmission.  

The modern scientific understanding of hantavirus disease expanded substantially after the 1993 Four Corners outbreak in the southwestern United States, during which Sin Nombre virus was identified as the etiologic agent of HCPS. Since then, molecular surveillance studies have identified multiple hantavirus species across Asia, Europe, and the Americas.  

Viral Taxonomy and Genomic Organization

Hantaviruses belong to:

• Order: Bunyavirales
• Family: Hantaviridae
• Genus: Orthohantavirus

The viral genome consists of three negative-sense RNA segments:

• Large (L)
• Medium (M)
• Small (S)

The genomic organization may be represented as:

Genome_{Hantavirus}=L+M+S

The segments encode:

• RNA-dependent RNA polymerase (L segment)
• Glycoproteins Gn and Gc (M segment)
• Nucleocapsid protein (S segment)

The viral envelope contains glycoproteins responsible for host-cell attachment and membrane fusion. Viral replication occurs predominantly within endothelial cells, contributing to vascular dysfunction and capillary leakage.  

Reservoir Hosts and Ecological Distribution

Each hantavirus species is associated with a distinct rodent reservoir host in which persistent asymptomatic infection occurs. Viral maintenance within rodent populations facilitates long-term environmental circulation.  

Examples include:

Hantavirus Species, Primary Reservoir, Geographic Distribution

Sin Nombre virus, Deer mouse (Peromyscus maniculatus), North America

Andes virus, Long-tailed pygmy rice rat, Argentina and Chile

Hantaan virus, Striped field mouse, East Asia

Puumala virus, Bank vole, Northern Europe

Seoul virus, Norway rat, Worldwide urban regions

Environmental conditions strongly influence spillover risk. Human exposure is associated with:

• Agricultural activity
• Forestry work
• Rodent-infested dwellings
• Camping
• Military training
• Cleaning enclosed contaminated environments

Transmission Dynamics

Rodent-to-Human Transmission

Human infection primarily occurs through inhalation of aerosolized viral particles from contaminated rodent excreta. Less common transmission routes include:

• Rodent bites
• Direct mucosal contact
• Contaminated food exposure

The generalized transmission pathway is summarized below:

Rodent\ Reservoir->Aerosolized\ Excreta-> Human Exposure

Activities involving poorly ventilated or enclosed contaminated spaces significantly increase infection risk.  

Human-to-Human Transmission

Most hantavirus species are not transmitted efficiently between humans. Andes virus remains the only strain with documented limited person-to-person transmission. Epidemiologic studies suggest transmission occurs primarily among:

• Household contacts
• Intimate partners
• Healthcare caregivers during close exposure

Transmission appears most likely during the prodromal phase of illness.  

Recent investigations surrounding the 2026 cruise ship outbreak involving the MV Hondius renewed scientific interest in Andes virus transmissibility. International health authorities reported several confirmed infections and fatalities among passengers traveling across multiple countries. Nevertheless, the World Health Organization currently assesses the overall public risk as low and does not consider the outbreak indicative of pandemic potential comparable to SARS-CoV-2.  

Clinical Manifestations

Hantavirus Cardiopulmonary Syndrome (HCPS)

HCPS predominates within the Americas and represents the most severe hantavirus-associated disease phenotype.

Prodromal Phase

Initial symptoms commonly include:

• Fever
• Myalgia
• Malaise
• Headache
• Nausea
• Abdominal pain

Symptoms typically appear between one and eight weeks following exposure.  

Cardiopulmonary Phase

Rapid disease progression may result in:

• Nonproductive cough
• Dyspnea
• Pulmonary edema
• Hypotension
• Cardiogenic shock

Case fatality rates for severe HCPS may approach 40–50%.  

Hemorrhagic Fever with Renal Syndrome (HFRS)

HFRS occurs predominantly in Europe and Asia and is characterized by:

• Fever
• Hemorrhage
• Hypotension
• Acute kidney injury
• Renal failure

Disease severity varies according to viral subtype:

• Hantaan virus causes severe disease
• Puumala virus commonly produces milder nephropathia epidemica

Reported mortality rates range from <1% to approximately 15%.  

Pathophysiology

The hallmark of hantavirus disease is increased vascular permeability caused by endothelial dysfunction. Unlike cytolytic viruses that directly destroy tissues, hantaviruses induce significant immune-mediated vascular leakage.

Major pathogenic mechanisms include:

• Cytokine dysregulation
• Endothelial activation
• Increased vascular permeability
• Coagulation abnormalities
• Pulmonary and systemic edema

The exaggerated host inflammatory response is believed to contribute substantially to disease severity.  

Diagnostic Approaches

Early diagnosis remains difficult because early symptoms overlap substantially with:

• Influenza
• COVID-19
• Viral pneumonia
• Leptospirosis
• Dengue fever
• Sepsis

Diagnostic modalities include:

Serologic Testing

• Detection of hantavirus-specific IgM antibodies
• Rising IgG titers

Molecular Diagnostics

• Reverse-transcription polymerase chain reaction (RT-PCR)

Clinical specimens require biosafety precautions because infectious viral particles may remain present in non-inactivated samples.  

Treatment and Clinical Management

No licensed curative antiviral therapy or universally approved vaccine currently exists for hantavirus infection.  

Current management is primarily supportive and may include:

• Supplemental oxygen
• Mechanical ventilation
• Hemodynamic stabilization
• Extracorporeal membrane oxygenation (ECMO)
• Renal replacement therapy for HFRS

Early intensive care intervention significantly improves survival outcomes in severe HCPS. Ribavirin and monoclonal antibody therapies remain under investigation but are not universally established standards of care.  

Epidemiology and Global Burden

Hantavirus infections remain relatively uncommon globally but continue to represent significant regional public health concerns.

Current WHO estimates suggest:

• Approximately 10,000–100,000 infections occur annually worldwide
• Asia and Europe account for the majority of HFRS cases
• The Americas report fewer HCPS cases but substantially higher mortality

Geographic Distribution

Americas

• HCPS predominates
• Hundreds of cases annually
• Mortality commonly between 20–40%

Europe and Asia

• HFRS predominates
• Thousands of annual infections
• Lower overall mortality rates

The United States has documented fewer than 1,000 cumulative HCPS cases since surveillance began.  

Current 2026 Outbreak Developments

International attention intensified in May 2026 following reports of Andes hantavirus transmission associated with the expedition cruise vessel MV Hondius. Several laboratory-confirmed infections and deaths were reported among passengers traveling internationally. Public health agencies initiated multinational contact tracing and monitoring protocols.  

Key observations from current investigations include:

• The outbreak is linked to Andes virus
• Limited human-to-human transmission remains biologically plausible
• Sustained airborne community transmission has not been demonstrated
• WHO currently considers overall global public risk low

Public concern has expanded substantially across online communities and social media platforms. However, infectious disease specialists emphasize that hantavirus transmission dynamics differ fundamentally from highly transmissible respiratory pathogens such as SARS-CoV-2.  

Prevention and Public Health Measures

Prevention strategies primarily focus on minimizing rodent exposure and environmental contamination.

Recommended interventions include:

• Rodent-proofing buildings
• Safe food storage
• Wet disinfection before cleanup
• Avoidance of dry sweeping contaminated areas
• Appropriate respiratory protection during high-risk cleaning

Healthcare prevention measures include:

• Early case identification
• Isolation precautions
• Monitoring close contacts
• Standard infection-control procedures

Future Research Directions

Current scientific priorities include:

• Vaccine development
• Broad-spectrum antiviral therapies
• Improved molecular diagnostics
• Viral phylogenetic surveillance
• Understanding immune-mediated vascular injury
• Ecological modeling of zoonotic spillover risk

Advances in genomic sequencing and international surveillance networks continue improving outbreak detection and epidemiologic response capabilities.  

Conclusion

Hantaviruses remain medically significant zoonotic RNA pathogens capable of producing severe cardiopulmonary and renal disease with high mortality in affected patients. Although infections remain relatively rare, recent outbreaks involving Andes hantavirus underscore the necessity for continued global surveillance, rapid diagnostics, rodent control initiatives, and coordinated international public health responses.

Current evidence indicates that hantavirus does not presently represent a pandemic level threat comparable to highly transmissible airborne respiratory viruses. Nonetheless, ecological disruption, environmental change, and increased human interaction with wildlife reservoirs may contribute to future zoonotic emergence events.

Continued research into antiviral therapeutics, vaccine platforms, molecular epidemiology, and host immune responses remains critical for reducing hantavirus-associated morbidity and mortality worldwide.  

References

1. World Health Organization – Hantavirus Fact Sheet
2. Centers for Disease Control and Prevention – Hantavirus Information
3. Centers for Disease Control and Prevention – About Hantavirus
4. National Institutes of Health – Hantavirus Pulmonary Syndrome Overview
5. National Center for Biotechnology Information – Hantaviruses: Clinical and Molecular Biology Review
6. Johns Hopkins Bloomberg School of Public Health – Hantavirus Overview
7. Mayo Clinic – Hantavirus Pulmonary Syndrome
8. Cleveland Clinic – Hantavirus: Symptoms, Causes, and Treatment
9. Nature Reviews Microbiology – Hantavirus Pathogenesis and Immunology
10. The Lancet – Hantavirus Infections in Humans: Epidemiology and Clinical Disease
11. Business Insider – WHO Monitoring 2026 Andes Hantavirus Cruise Outbreak
12. Washington Post – International Contact Tracing Following Andes Hantavirus Cases
13. PubMed – Hantavirus Pulmonary Syndrome: Pathogenesis and Clinical Features
14. PubMed – Andes Virus Person-to-Person Transmission Studies
15. European Centre for Disease Prevention and Control – Hantavirus Factsheet